Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc. (NASDAQ: RVMD), sold 12,871 shares of the company's common stock on March 17, 2026, at $99.4804 per share, resulting in proceeds of approximately $1.28 million. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission and was carried out under a Rule 10b5-1 trading plan that Goldsmith adopted on May 31, 2023.
According to the filing, the 10b5-1 plan was established specifically to meet tax liabilities associated with the vesting of restricted stock units (RSUs). The sale was executed while Revolution Medicines' shares were trading near a 52-week high of $124.49, following a reported 156% gain over the last 12 months.
After completing the March 17 sale, Goldsmith directly holds 276,698 shares of Revolution Medicines, which include 201,150 RSUs. He also maintains indirect holdings through several revocable trusts: 594,060 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, 64,424 shares through the Jonathan Goldsmith Revocable Trust, and 64,424 shares through the Rebecca Goldsmith Revocable Trust.
Separately, company financial disclosures and third-party analysis cited in recent reporting indicate that Revolution Medicines ended the fourth quarter of 2025 with $2.03 billion in cash and investments. That cash position, supported by a strategic partnership with Royalty Pharma, is said to exceed the company's debt load despite the firm remaining unprofitable.
Revolution Medicines' Q4 2025 results showed an 87% year-over-year increase in net loss, with reported earnings per share of negative $1.86. That EPS figure missed the consensus estimate of negative $1.58, with the shortfall attributed primarily to higher-than-expected research and development expenses.
Analyst reaction following the earnings release has been broadly supportive. UBS initiated coverage of the company with a Buy rating, citing the therapeutic potential of its RAS inhibitors across solid tumors. Piper Sandler raised its price target on the shares to $120 and retained an Overweight rating. Needham adjusted its price target to $145 while maintaining a Buy rating, noting increased costs but keeping a positive stance. Wells Fargo lifted its price target to $144 and conveyed confidence in the company's progress toward its first pivotal readout anticipated in early 2026. These analyst moves were described as reflecting continued confidence in Revolution Medicines' strategy and pipeline advancement.
In addition to public reporting and analyst commentary, one investment research platform referenced in filings offers 12 additional "ProTips" for investors seeking deeper insight into the company's prospects, and indicated that the firm's balance sheet contains more cash than debt even as it operates at a loss.
The Form 4 filing and the details of Goldsmith's sale reinforce that the transaction was pre-arranged and designated for tax coverage tied to equity compensation. Beyond that procedural context, the company's recent financial results and the ensuing analyst activity are the primary public developments shaping investor attention.
Contextual note: The disclosure of this sale and the company's financial and analyst developments are factual as reported in regulatory filings and company announcements.